Monaco Asset Management SAM Has $1.45 Million Holdings in Novavax, Inc. $NVAX

Monaco Asset Management SAM cut its stake in Novavax, Inc. (NASDAQ:NVAX) by 20.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 230,000 shares of the biopharmaceutical company’s stock after selling 60,000 shares during the period. Monaco Asset Management SAM owned approximately 0.14% of Novavax worth $1,449,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Signaturefd LLC lifted its stake in shares of Novavax by 47.2% in the second quarter. Signaturefd LLC now owns 9,739 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 3,122 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new position in Novavax in the 2nd quarter valued at approximately $73,000. Bank Julius Baer & Co. Ltd Zurich acquired a new position in Novavax in the 1st quarter valued at approximately $71,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Novavax in the 2nd quarter worth approximately $72,000. Finally, Kapitalo Investimentos Ltda acquired a new stake in shares of Novavax during the 2nd quarter worth approximately $79,000. Institutional investors own 53.04% of the company’s stock.

Novavax Trading Down 2.0%

Shares of NVAX stock opened at $7.44 on Friday. The company has a market capitalization of $1.21 billion, a P/E ratio of 3.26, a P/E/G ratio of 0.12 and a beta of 2.68. Novavax, Inc. has a 12-month low of $5.01 and a 12-month high of $11.55. The company has a quick ratio of 2.34, a current ratio of 2.36 and a debt-to-equity ratio of 5.93. The firm has a 50-day moving average price of $8.39 and a 200 day moving average price of $7.58.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($1.08) by ($0.17). Novavax had a negative return on equity of 142.33% and a net margin of 39.20%.The firm had revenue of $70.45 million for the quarter, compared to analyst estimates of $55.63 million. During the same period in the previous year, the business posted ($0.76) EPS. The business’s quarterly revenue was down 16.7% on a year-over-year basis. Novavax has set its FY 2025 guidance at EPS. Research analysts forecast that Novavax, Inc. will post -1.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Bank of America restated an “underperform” rating and issued a $7.00 target price (down from $9.00) on shares of Novavax in a research note on Wednesday, August 20th. Wall Street Zen lowered shares of Novavax from a “hold” rating to a “sell” rating in a report on Saturday. TD Cowen reduced their price objective on shares of Novavax from $8.00 to $7.00 and set a “hold” rating for the company in a report on Tuesday, November 4th. Cantor Fitzgerald assumed coverage on shares of Novavax in a research report on Friday, October 24th. They set an “overweight” rating and a $18.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Novavax in a research note on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $10.71.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.